NEW YORK CITY, NY / ACCESSWIRE / December 10, 2018 / Dwight Egan, CEO of Co-Diagnostics Inc, (CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, discussed the expectation for sales before the end of 2018 in a recent virtual investor conference.
The conference began with a discussion of milestones in 2018, about which Mr. Egan remarked: "We feel that some of these announcements are significant enough that they could represent a defining achievement of any given fiscal quarter, if not year. When you consider where we began 2018 and the growth we've shown, as illustrated by these milestones, we are confident that we are on the right path and that this is just the beginning."
In addition to expectations for revenue in 2018 and 2019, questions from the audience included those related to progress of the Joint Venture facility for manufacturing in India, the status of the company's efforts in India and the Caribbean, an explanation of LGC's importance to the AgBio industry to validating the company's technology, the regulatory landscape for the company's products, and the potential for licensing revenue of the company's technology.
Access to an archived version of the conference is available through the Company's Events and Presentations page.
Access to the Wall Street Club Interview remains available here
About The Wall Street Club:
The Wall Street Club (WSC) is a financial digital media company whose focus is to provide readers with news and content on the latest trends and happenings in the financial industry. WSC writes about stocks in both free and paid content. WSC accepts sole responsibility for the content and distribution of the foregoing release.
The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the Wall Street Club may at times hold a position in the company covered within the article. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words "anticipate," "intend," "estimate," "believe," "expect," "plans," "should," "potential," "forecast," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. The Wall Street Club is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
The Wall Street Club
SOURCE: Co-Diagnostics Inc.